Breaking News Instant updates and real-time market news.

ONCE

Spark Therapeutics

$77.63

3.84 (5.20%)

, BMRN

BioMarin

$97.94

-1.53 (-1.54%)

08:18
08/07/18
08/07
08:18
08/07/18
08:18

Spark sinks after mean hemophilia study dose response comes in at 30%

Shares of Spark Therapeutics (ONCE) are sinking after the company announced preliminary Phase 1/2 data for its investigational gene therapy candidate SPK-8011 for hemophilia A. A dose response as demonstrated by FVIII expression ranged from 16% to 49%, with a mean of 30% post 12 weeks in five of the participants in the 2x1012 vg/kg cohort, Spark announced in its Q2 earnings release. RBC analyst Kennen MacKay last month pegged Street expectations at mean levels of 30% to 55%, according to Bloomberg. Following the data, shares of Spark Therapeutics are down 27%, or $20.61, to $57.00 in premarket trading. BioMarin Pharmaceutical (BMRN), which has a competing gene therapy hemophilia A treatment in development, is seeing its stock rise 6%, or $6.05, to $104.00.

ONCE

Spark Therapeutics

$77.63

3.84 (5.20%)

BMRN

BioMarin

$97.94

-1.53 (-1.54%)

  • 07

    Aug

  • 07

    Aug

  • 10

    Sep

  • 12

    Sep

ONCE Spark Therapeutics
$77.63

3.84 (5.20%)

07/16/18
CANT
07/16/18
NO CHANGE
Target $103
CANT
Overweight
Start of Pfizer trial encouraging for Spark Therapeutics, says Cantor Fitzgerald
After Spark Therapeutics (ONCE) announced that partner Pfizer (PFE) initiated a Phase 3 study to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting, Cantor Fitzgerald analyst Elemer Piros said he was encouraged that the program transfer is on track and he remains bullish on the fidanacogene elaparvovec program. He reiterates his Overweight rating and $103 price target on Spark shares.
07/19/18
RBCM
07/19/18
DOWNGRADE
RBCM
Sector Perform
Spark Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
07/19/18
RBCM
07/19/18
DOWNGRADE
Target $75
RBCM
Sector Perform
Spark Therapeutics cut to Sector Perform at RBC Capital on SPK-801 concern
As reported earlier, RBC Capital analyst Kennen MacKay downgraded Spark Therapeutics to Sector Perform from Outperform and kept his $75 price target. The analyst notes that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." McKay also cites the possibility of regulatory delays to gain approval for sale of Luxturna among the risks for Spark Therapeutics.
07/19/18
07/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Hold at Needham with analyst Rajvindra Gill saying the stock remains overvalued in spite of its 16% decline from the the June 2017 peak. 2. Procter & Gamble (PG) downgraded to Neutral from Buy at UBS with analyst Steven Strycula saying the company's reinvestment cycle limits earnings and stock upside. 3. Terex (TEX) downgraded to Market Perform from Outperform at Wells Fargo with analyst Andrew Casey saying his crane check was good but not great, with demand appearing to sequentially flatten. 4. Spark Therapeutics (ONCE) downgraded to Sector Perform from Outperform at RBC Capital with analyst Kennen MacKay saying that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." 5. Hyatt (H) downgraded to Hold from Buy at Berenberg with analyst El Kassir saying Hyatt continues to benchmark well on its pipeline, however, there is little scope for future growth to accelerate from current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BMRN BioMarin
$97.94

-1.53 (-1.54%)

05/29/18
SBSH
05/29/18
NO CHANGE
Target $108
SBSH
Buy
BioMarin price target raised to $108 from $100 at Citi
Citi analyst Robyn Karnauskas raised her price target for Biomarin Pharmaceutical to $108 following the approval of Palynziq. The drug received a broad label and monitoring only for a single dose can accelerate patient uptake, Karnauskas tells investors in a research note. She keeps a Buy rating on BioMarin shares.
08/03/18
PIPR
08/03/18
NO CHANGE
Target $120
PIPR
Overweight
BioMarin price target raised to $120 from $114 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for BioMarin Pharmaceutical to $120 and keeps an Overweight rating on the name following the company's "solid" Q2 results. The analyst believes the Palynziq launch is going well and says BioMarin provided incrementally positive updates for hemophilia gene therapy candidate valrox. He sees a "credible chance" that BioMarin could file early for accelerated approval on valrox Phase 1 data. Raymond continues to like to setup for the stock and would be a buyer to levels approaching $120.
08/06/18
WEDB
08/06/18
NO CHANGE
Target $120
WEDB
Outperform
BioMarin price target raised to $120 from $115 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for BioMarin to $120 from $115 after the company reported "solid" Q2 results. The analyst reiterates an Outperform rating on the shares.
08/07/18
STFL
08/07/18
INITIATION
Target $114
STFL
Buy
BioMarin transferred with a Buy at Stifel
Stifel transferred coverage of BioMarin to analyst Paul Matteis, who set a Buy rating and $114 price target on the shares. He sees the approved product base having a path to about $2B in 2019 revenue, which provides a share floor of about $80 ahead of a handful of clinical catalysts during the next 12-18 months, Matteis tells investors. BioMarin is better positioned than most mature biotechs in terms of drug pricing pressure and competition risk, added the analyst.

TODAY'S FREE FLY STORIES

10:35
08/15/18
08/15
10:35
08/15/18
10:35
General news
Fed funds futures are rallying »

Fed funds futures are…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.80

-3 (-1.06%)

10:33
08/15/18
08/15
10:33
08/15/18
10:33
Technical Analysis
Technical Take: SPDR S&P 500 ETF breaks additional support »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.80

-3 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

$113.29

0.19 (0.17%)

, MAR

Marriott

$119.80

-1.78 (-1.46%)

10:32
08/15/18
08/15
10:32
08/15/18
10:32
Hot Stocks
Marriott expands PepsiCo relationship with new multiyear deal »

PepsiCo (PEP) and…

PEP

PepsiCo

$113.29

0.19 (0.17%)

MAR

Marriott

$119.80

-1.78 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HMNY

Helios and Matheson

$0.04

-0.0135 (-27.00%)

10:32
08/15/18
08/15
10:32
08/15/18
10:32
Hot Stocks
Helios and Matheson: Creating a 'more sustainable path' for MoviePass »

"We far exceeded our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.04

-0.0141 (-28.20%)

10:31
08/15/18
08/15
10:31
08/15/18
10:31
Hot Stocks
Helios and Matheson issues progress report on MoviePass »

Helios and Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:31
08/15/18
08/15
10:31
08/15/18
10:31
General news
Crude inventories for week of August 10 »

Crude oil inventories…

BSX

Boston Scientific

$34.05

0.36 (1.07%)

10:30
08/15/18
08/15
10:30
08/15/18
10:30
Options
Bullish option play in Boston Scientific as shares see relative strength »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 20

    Aug

  • 23

    Aug

10:30
08/15/18
08/15
10:30
08/15/18
10:30
General news
The 0.1% U.S. June business inventory rise »

The 0.1% U.S. June…

10:30
08/15/18
08/15
10:30
08/15/18
10:30
General news
U.S. VIX not dead yet, surging 20% »

U.S. VIX not dead yet,…

WEN

Wendy's

$17.71

-0.13 (-0.73%)

10:28
08/15/18
08/15
10:28
08/15/18
10:28
Conference/Events
Wendy's participates in a conference call with Stephens »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

CUR

Neuralstem

$1.19

(0.00%)

10:27
08/15/18
08/15
10:27
08/15/18
10:27
Earnings
Neuralstem reports Q2 EPS (4c) vs. (39c) last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
08/15/18
08/15
10:25
08/15/18
10:25
Conference/Events
Vertical Group analyst to hold an analyst/industry conference call »

Metals/Mining &…

WMT

Walmart

$89.74

-1.065 (-1.17%)

, AMZN

Amazon.com

$1,892.64

-27.08 (-1.41%)

10:24
08/15/18
08/15
10:24
08/15/18
10:24
Earnings
On The Fly: What to watch in Wal-Mart earnings report »

WalMart (WMT) is…

WMT

Walmart

$89.74

-1.065 (-1.17%)

AMZN

Amazon.com

$1,892.64

-27.08 (-1.41%)

NFLX

Netflix

$328.11

-9.38 (-2.78%)

MSFT

Microsoft

$107.48

-1.67 (-1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

EVBG

Everbridge

$54.40

-0.04 (-0.07%)

10:23
08/15/18
08/15
10:23
08/15/18
10:23
Conference/Events
Everbridge management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

NVDA

Nvidia

$258.69

-2.78 (-1.06%)

, WDC

Western Digital

$61.75

-3.23 (-4.97%)

10:22
08/15/18
08/15
10:22
08/15/18
10:22
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

NVDA

Nvidia

$258.69

-2.78 (-1.06%)

WDC

Western Digital

$61.75

-3.23 (-4.97%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GWPH

GW Pharmaceuticals

$132.44

-1.04 (-0.78%)

HAS

Hasbro

$97.55

-0.59 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WU

Western Union

$18.74

-0.075 (-0.40%)

10:20
08/15/18
08/15
10:20
08/15/18
10:20
Options
Put buyers in Western Union »

Put buyers in Western…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

M

Macy's

$37.10

-4.77 (-11.39%)

10:17
08/15/18
08/15
10:17
08/15/18
10:17
Hot Stocks
Macy's says SG&A dollars for the year expected to be higher than last year »

CFO Paula Price says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 17

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
08/15/18
08/15
10:17
08/15/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CISN

Cision

$16.33

0.07 (0.43%)

, OBSV

ObsEva

$13.25

0.27 (2.08%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

CISN

Cision

$16.33

0.07 (0.43%)

OBSV

ObsEva

$13.25

0.27 (2.08%)

IDRA

Idera Pharmaceuticals

$9.06

0.545 (6.40%)

DTE

DTE Energy

$112.00

0.97 (0.87%)

TELL

Tellurian

$7.10

-0.01 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

NLSN

Nielsen

$25.50

-0.57 (-2.19%)

, UNP

Union Pacific

$148.61

-1.56 (-1.04%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

NLSN

Nielsen

$25.50

-0.57 (-2.19%)

UNP

Union Pacific

$148.61

-1.56 (-1.04%)

KMB

Kimberly-Clark

$113.90

2.8 (2.52%)

WDC

Western Digital

$61.77

-3.21 (-4.94%)

TSRO

Tesaro

$27.70

-0.37 (-1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 26

    Aug

  • 06

    Nov

NVDA

Nvidia

$259.49

-1.98 (-0.76%)

, HAS

Hasbro

$97.66

-0.48 (-0.49%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NVDA

Nvidia

$259.49

-1.98 (-0.76%)

HAS

Hasbro

$97.66

-0.48 (-0.49%)

INCY

Incyte

$67.21

0.76 (1.14%)

NSC

Norfolk Southern

$171.79

-0.39 (-0.23%)

PZZA

Papa John's

$42.50

-0.5 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 26

    Aug

  • 06

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
U.S. NAHB housing market index fell 1 tick to 67 in August »

U.S. NAHB housing market…

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
Treasury Action: yields slumped back to lows »

Treasury Action: yields…

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
Breaking General news story  »

Week of 8/10 EIA…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.